HT
ALLO icon

Headlands Technologies’s Allogene Therapeutics ALLO Stock Holding History

Headlands Technologies’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$649K Buy
265,922
+219,144
+468% +$439K 0.07% 303
2025
Q4 		$64.1K Sell
46,778
-93,183
-67% -$123K 0.01% 645
2025
Q3 		$174K Buy
+139,961
New +$167K 0.01% 547
2024
Q2 		– Sell
-17,396
Closed -$77.8K – 1123
2024
Q1 		$77.8K Buy
+17,396
New +$72.6K 0.02% 604

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Headlands Technologies's ALLO Position: Q1 2026 in Review

Headlands Technologies increased its Allogene Therapeutics (ALLO) stake by 468% in Q1 2026, buying an estimated $439K and bringing the position to 265,922 shares worth $649K. The position accounts for 0.07% of the portfolio, ranked #303.

Headlands Technologies first reported a position in ALLO in Q1 2024 and has held it in 4 quarters since. 208 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Headlands Technologies held 265,922 shares of Allogene Therapeutics worth $649K as of Q1 2026.
  • Headlands Technologies bought 219,144 Allogene Therapeutics shares in Q1 2026, an estimated $439K.
  • Allogene Therapeutics made up 0.07% of Headlands Technologies's portfolio in Q1 2026, its #303 holding.
  • Headlands Technologies first reported a position in Allogene Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • 208 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.